# Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)

Study · id `cardio:ct-nct01761786` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01761786](<https://clinicaltrials.gov/study/NCT01761786>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01761786

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2700 participants.

## Technical summary

Registry record NCT01761786. Randomized; single masking; primary purpose treatment. Start 2011-06 (actual); primary completion 2019-04-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2700 participants (enrolled count; ClinicalTrials.gov record NCT01761786, source copy `cardio:ctgov-nct01761786-2019-05-10`, retrieved 2026-10-26)
- Started: 2011-06 (actual) (ClinicalTrials.gov record NCT01761786, source copy `cardio:ctgov-nct01761786-2019-05-10`, retrieved 2026-10-26)
- Primary completion: 2019-04-04 (actual) (ClinicalTrials.gov record NCT01761786, source copy `cardio:ctgov-nct01761786-2019-05-10`, retrieved 2026-10-26)
- Completion: 2019-04-04 (actual) (ClinicalTrials.gov record NCT01761786, source copy `cardio:ctgov-nct01761786-2019-05-10`, retrieved 2026-10-26)
- Countries: Belgium; Italy; Netherlands (ClinicalTrials.gov record NCT01761786, source copy `cardio:ctgov-nct01761786-2019-05-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01761786-2019-05-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)
- Condition: Myocardial Infarction
- Condition: STEMI
- Intervention (Genetic): CYP2C19 genotyping
- Lead sponsor: Vera HM Deneer
- Lead sponsor class: OTHER
- Collaborator: Isala
- Collaborator class: OTHER
- Collaborator: Meander Medical Center
- Collaborator class: OTHER
- Collaborator: UMC Utrecht
- Collaborator class: OTHER
- Collaborator: University Medical Center Groningen
- Collaborator class: OTHER
- Collaborator: OLVG
- Collaborator class: NETWORK
- Collaborator: Onze Lieve Vrouw Hospital
- Collaborator class: OTHER
- Collaborator: Amphia Hospital
- Collaborator class: OTHER
- Collaborator: ZonMw: The Netherlands Organisation for Health Research and Development
- Collaborator class: OTHER
- Collaborator: Federico II University
- Collaborator class: OTHER
- Collaborator: Rijnstate Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as a collaborator: Isala (`cardio:org-isala`)
- Registry lists this organization as a collaborator: UMC Utrecht (`cardio:org-umc-utrecht`)
- Registry lists this organization as a collaborator: University Medical Center Groningen (`cardio:org-university-medical-center-groningen`)
- Registry lists this organization as a collaborator: Onze Lieve Vrouw Hospital (`cardio:org-onze-lieve-vrouw-hospital`)
- Registry lists this organization as a collaborator: Amphia Hospital (`cardio:org-amphia-hospital`)
- Registry lists this organization as a collaborator: ZonMw: The Netherlands Organisation for Health Research and Development (`cardio:org-zonmw-the-netherlands-organisation-for-health-research-and-cc2e75`)
- Registry lists this organization as a collaborator: Federico II University (`cardio:org-federico-ii-university`)
- Registry lists this organization as a collaborator: Rijnstate Hospital (`cardio:org-rijnstate-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI (`cardio:pubmed-31479209`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: b8e5dd0262598d1c35f01b4e57e950f0639f9116129b802e108ba4fde1e0a25f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
